- What Does My BMI Have to Be to Get Saxenda? FDA prescribing criteria require an initial BMI ≥ 30 kg/m² (obesity), OR a BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity (hypertension, type 2 diabetes, or dyslipidemia).
- Is Saxenda Dosed Daily or Weekly? Saxenda is dosed once daily (365 injections/year) because liraglutide has a 13-hour half-life. Semaglutide and tirzepatide are injected once weekly (52 injections/year) due to a ~165-hour (7-day) half-life.
- Semaglutide vs. Saxenda Weight Loss (STEP-8): In head-to-head trials, weekly semaglutide 2.4 mg produced 15.8% weight loss vs. just 6.4% for daily Saxenda 3.0 mg (and 8.0% in the SCALE trial). Semaglutide Wins
- Greatest Weight Reduction Among Incretin Mimetics: Dual GIP/GLP-1 agonist Tirzepatide 15 mg weekly leads all FDA-approved incretin mimetics with 20.9%–22.5% weight loss (SURMOUNT-1), available in compounded form at Losing Weight RX for $129/mo alongside $79/mo Semaglutide. LW RX Value
What Does My BMI Have to Be to Get Saxenda? (FDA Criteria)
Patients researching GLP-1 weight loss therapy frequently ask: "what does my BMI have to be to get Saxenda?" Under FDA-approved prescribing information, adult patients qualify for Saxenda® (liraglutide 3.0 mg injection) if they meet either of two clinical Body Mass Index (BMI) thresholds:
- BMI of 30.0 kg/m² or higher (Obesity): Qualifies for Saxenda (as well as semaglutide or tirzepatide) without requiring an additional weight-related medical condition. For example, an adult who is 5'6" tall reaches a BMI of 30.0 at approximately 186 lbs.
- BMI of 27.0 to 29.9 kg/m² (Overweight) + 1 Comorbidity: Qualifies if you also have at least one weight-related medical condition (dysglycemia/prediabetes, type 2 diabetes mellitus, hypertension/high blood pressure, dyslipidemia/high cholesterol, or obstructive sleep apnea). At 5'6", a BMI of 27.0 corresponds to approximately 167 lbs.
- Pediatric Criteria (Ages 12–17): Body weight above 60 kg (132 lbs) and an initial BMI corresponding to 30 kg/m² or greater for adults by international cut-offs.
Unlike weekly semaglutide or tirzepatide protocols, FDA labeling for Saxenda includes a strict 16-week evaluation rule: if a patient has not lost at least 4% of baseline body weight after 16 weeks on Saxenda, clinicians are instructed to discontinue the medication because the patient is unlikely to achieve clinically meaningful weight loss with continued daily liraglutide injections.
Do Saxenda Injections Happen Daily, Weekly, or on Another Schedule?
One of the most common points of confusion for patients comparing GLP-1 medications is injection frequency: "is Saxenda dosed daily?", "is Saxenda daily or weekly?", and "do Saxenda injections happen daily, weekly, or on another schedule?"
Saxenda injections happen once daily (every 24 hours). Unlike newer second- and third-generation GLP-1 therapies such as semaglutide (Wegovy® / Ozempic®) and tirzepatide (Zepbound® / Mounjaro®)—which are injected just once per week—Saxenda must be injected every single day at any time of day, independent of meals.
5-Week Saxenda Daily Titration Schedule
To reduce gastrointestinal side effects like nausea, Saxenda requires a 5-week daily dose escalation schedule before reaching the 3.0 mg maintenance dose:
- Week 1: 0.6 mg injected once daily (7 injections)
- Week 2: 1.2 mg injected once daily (7 injections)
- Week 3: 1.8 mg injected once daily (7 injections)
- Week 4: 2.4 mg injected once daily (7 injections)
- Week 5 & Onward (Maintenance): 3.0 mg injected once daily (365 injections per year)
Why Does Liraglutide Need to Be Injected Every Day, Rather Than Once a Week?
A frequent pharmacology and clinical question is: "why does liraglutide need to be injected every day, rather than once a week?" The answer comes down to molecular peptide engineering, DPP-4 enzymatic breakdown, and serum albumin binding affinity.
Endogenous human GLP-1 (the natural hormone your gut secretes after eating) has an ultra-short half-life of only 1.5 to 2 minutes in the bloodstream because an enzyme called dipeptidyl peptidase-4 (DPP-4) rapidly cleaves the peptide at the alanine residue at position 8 (Ala8), and the kidneys clear it immediately.
- Why Liraglutide (Saxenda) Lasts Only 13 Hours (Daily Dosing): Liraglutide shares 97% amino acid sequence homology with native human GLP-1. To slow down degradation, chemists attached a 16-carbon (C16) palmitic fatty monoacid chain at position 26 via a glutamic acid spacer. This C16 fatty acid allows liraglutide to self-associate into heptamers at the subcutaneous injection site and bind reversibly to circulating albumin in the bloodstream. However, because liraglutide retains the native alanine at position 8 (Ala8) and uses a shorter C16 monoacid chain, it remains partially vulnerable to DPP-4 cleavage when unbound from albumin—resulting in a plasma elimination half-life of roughly 13 hours. After 24 hours, blood levels drop too low to suppress appetite, requiring a daily injection.
- Why Semaglutide & Tirzepatide Last ~165 Hours / 7 Days (Weekly Dosing): To transform liraglutide into a once-weekly molecule, biochemists made two decisive structural upgrades in semaglutide: (1) they replaced alanine at position 8 with a synthetic amino acid called alpha-aminoisobutyric acid (Aib8), which sterically blocks the DPP-4 enzyme from cutting the peptide, and (2) they replaced the C16 monoacid chain with a longer, higher-affinity C18 octadecanedioic fatty diacid chain linked via a hydrophilic PEG spacer. This locks semaglutide onto human serum albumin with vastly greater affinity, shielding it from renal clearance and extending its half-life from 13 hours to ~165 hours (approximately 7 days). Tirzepatide uses a similar C20 eicosanedioic fatty diacid moiety to achieve a ~5-day (120-hour) half-life for once-weekly dosing.
Get Once-Weekly Semaglutide ($79/mo) or Tirzepatide ($129/mo)
Why inject yourself every single day with Saxenda for 6.4%–8.0% weight loss? Switch to once-weekly Compounded Semaglutide ($79/mo) or Tirzepatide ($129/mo) through Losing Weight RX with $0 membership fees and flat-rate dosing.
Check Your BMI EligibilitySemaglutide vs. Saxenda: How Much Weight Can You Lose With Saxenda Injections?
When patients ask "how much weight can you lose with Saxenda injections?" or compare "semaglutide vs Saxenda", we don't have to guess—we have both standalone Phase 3 clinical trials (SCALE and STEP-1) and a direct head-to-head randomized clinical trial (STEP-8, published in JAMA).
- Saxenda (Liraglutide 3.0 mg Daily) Weight Loss: In the 56-week Phase 3 SCALE Obesity and Prediabetes trial (n = 3,731), patients injecting Saxenda 3.0 mg daily lost a mean of 8.0% of their baseline body weight (~18.5 lbs), compared to 2.6% with placebo.
- Head-to-Head STEP-8 Trial (Semaglutide 2.4 mg Weekly vs. Saxenda 3.0 mg Daily): In the 68-week STEP-8 trial (Rubino et al., JAMA 2022), researchers directly randomized adults with obesity to either once-weekly semaglutide 2.4 mg or once-daily liraglutide 3.0 mg (Saxenda). The results were decisive:
- Once-Weekly Semaglutide 2.4 mg: -15.8% mean body weight reduction (~33.7 lbs)
- Once-Daily Saxenda (Liraglutide 3.0 mg): -6.4% mean body weight reduction (~15.0 lbs)
- Proportion Losing ≥10% Body Weight: 70.9% of semaglutide patients vs. only 25.6% of Saxenda patients
- Proportion Losing ≥20% Body Weight: 38.5% of semaglutide patients vs. only 6.0% of Saxenda patients
Additionally, treatment discontinuation was significantly higher in the daily Saxenda group (27.6% stopped treatment prematurely) compared to the weekly semaglutide group (13.5%), driven by injection fatigue from daily needles and frustrated expectations.
Which Therapy Shows the Greatest Mean Percentage Weight Reduction in Clinical Trials Among Currently FDA-Approved Incretin Mimetics for Obesity?
In medical board reviews and clinical obesity comparisons, a key benchmark question is: "Which therapy shows the greatest mean percentage weight reduction in clinical trials among currently FDA-approved incretin mimetics for obesity?"
The answer is Tirzepatide (a dual GIP and GLP-1 receptor co-agonist), which achieved a 20.9% to 22.5% mean percentage weight reduction at the 15 mg once-weekly maintenance dose over 72 weeks in the landmark SURMOUNT-1 Phase 3 trial (Jastreboff et al., NEJM 2022). Here is the complete hierarchy of FDA-approved incretin mimetics ranked by mean percentage weight reduction:
- Tirzepatide 15 mg Once Weekly (Dual GIP/GLP-1 Agonist — SURMOUNT-1): 20.9% (treatment-regimen estimand) to 22.5% (efficacy estimand) mean body weight reduction (~52 lbs).
- Tirzepatide 10 mg Once Weekly (SURMOUNT-1): 19.5% to 21.4% mean body weight reduction.
- Tirzepatide 5 mg Once Weekly (SURMOUNT-1): 15.0% to 16.0% mean body weight reduction.
- Semaglutide 2.4 mg Once Weekly (Selective GLP-1 Agonist — STEP-1 & STEP-8): 14.9% to 15.8% mean body weight reduction (~33–35 lbs).
- Liraglutide 3.0 mg Once Daily (Saxenda® — SCALE & STEP-8): 6.4% to 8.0% mean body weight reduction (~15–18.5 lbs).
Cost Comparison: Saxenda ($1,349/mo) vs. Losing Weight RX ($79/mo)
Despite producing less than half the weight loss of semaglutide and one-third the weight loss of tirzepatide, brand-name Saxenda carries an uninsured retail list price of roughly $1,349 per month for a 5-pen pack (and authorized generic liraglutide pens still cost $400–$800/month out of pocket at retail pharmacies).
| Clinical & Cost Metric | Semaglutide / Tirzepatide (Losing Weight RX) | Saxenda® (Liraglutide 3.0 mg) |
|---|---|---|
| Active Molecule & Class | Semaglutide (GLP-1) or Tirzepatide (Dual GIP/GLP-1) | Liraglutide (1st-generation GLP-1 agonist) |
| BMI Qualification Criteria | BMI ≥ 30, or BMI ≥ 27 with 1 weight comorbidity | BMI ≥ 30, or BMI ≥ 27 with 1 weight comorbidity |
| Injection Schedule | Once Weekly (52 injections per year) | Once Daily (365 injections per year) |
| Elimination Half-Life | ~165 hours / 7 days (Sema) • ~120 hours (Tirz) | ~13 hours (Requires daily injection) |
| Mean Clinical Trial Weight Loss | 14.9%–15.8% (Semaglutide) • 20.9%–22.5% (Tirzepatide) | 6.4%–8.0% (STEP-8 & SCALE trials) |
| Patients Losing ≥10% Body Weight | 70.9% (Semaglutide) • 89% (Tirzepatide 15 mg) | 25.6%–33.1% |
| Monthly Out-of-Pocket Cost | $79/mo (Semaglutide) or $129/mo (Tirzepatide) | ~$1,349/mo brand ($400–$800/mo generic) |
| Membership & Shipping Fees | $0 (100% All-Inclusive) | Varies by clinic and pharmacy |
Frequently Asked Questions (FAQs)
To qualify for Saxenda (liraglutide 3.0 mg) under FDA guidelines, adults must have either an initial Body Mass Index (BMI) of 30 kg/m² or greater (obesity), OR a BMI of 27.0 to 29.9 kg/m² (overweight) accompanied by at least one weight-related medical condition such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
Saxenda injections happen once daily (every 24 hours), not weekly. Yes, Saxenda is dosed daily—meaning patients must administer 365 subcutaneous injections per year, compared to just 52 once-weekly injections per year with semaglutide or tirzepatide.
Liraglutide (Saxenda) must be injected every day because its elimination half-life is only 13 hours. Liraglutide uses a C16 palmitic fatty acid chain with a glutamic acid spacer that binds reversibly to blood albumin, slowing DPP-4 breakdown for only about one day. By contrast, semaglutide features an Aib8 amino acid substitution (blocking DPP-4 cleavage) plus a C18 fatty diacid chain that binds tightly to albumin, extending its half-life to ~165 hours (7 days) for once-weekly dosing.
In the 56-week Phase 3 SCALE Obesity and Prediabetes trial, adults on Saxenda 3.0 mg daily lost an average of 8.0% of their body weight (~18.5 lbs). In the head-to-head 68-week STEP 8 randomized clinical trial comparing semaglutide vs. Saxenda directly, once-weekly semaglutide 2.4 mg achieved 15.8% mean weight loss compared to just 6.4% for daily Saxenda 3.0 mg—meaning semaglutide produced nearly 2.5 times greater weight reduction.
Among currently FDA-approved incretin mimetics for obesity, Tirzepatide (a dual GIP/GLP-1 receptor co-agonist) demonstrates the greatest mean percentage weight reduction in Phase 3 clinical trials: 20.9% to 22.5% mean body weight loss at the 15 mg weekly dose (and 15.0% at 5 mg weekly) over 72 weeks in SURMOUNT-1. Second is once-weekly Semaglutide 2.4 mg at 14.9% to 15.8% (STEP 1 and STEP 8), followed by once-daily Liraglutide 3.0 mg (Saxenda) at 6.4% to 8.0% (STEP 8 and SCALE).
Retail brand-name Saxenda costs approximately $1,349 per month out of pocket, and generic liraglutide pens typically run $400 to $800/month without insurance. Losing Weight RX provides once-weekly Compounded Semaglutide for a flat $79/month and Compounded Tirzepatide for $129/month across all dosage tiers with $0 membership fees and free cold-chain shipping.
Start Once-Weekly Semaglutide ($79/mo) or Tirzepatide ($129/mo) Today
Skip daily Saxenda needles and $1,349/mo pharmacy bills. Complete our 5-minute online assessment to see if your BMI qualifies for once-weekly GLP-1 treatment prescribed by a licensed U.S. clinician.
Get Started Today
Clinical References & Sources
- Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. JAMA Study
- Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes). New England Journal of Medicine, 373(1), 11–22. NEJM Study
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 384(11), 989–1002. NEJM Study
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 387(3), 205–216. NEJM Study